Physician profile
Daniel L Biery
NPI 1952323339
$2,331.06
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $126 · 2020: $200 · 2021: $1,328 · 2022: $598 · 2023: $78.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $78.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $78.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $460.18 | 2019-2023 | Skyrizi |
| Ambu INC. | $433.07 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $268.63 | 2020-2023 | Entyvio |
| Boston Scientific Corporation | $263.09 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $223.29 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $189.02 | 2021-2022 | |
| Janssen Biotech, INC. | $91.24 | 2019-2022 | |
| Gilead Sciences, INC. | $85.70 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $83.14 | 2022 | |
| Qol Medical, LLC | $40.38 | 2019-2021 | |
| Allergan, INC. | $36.00 | 2020 | |
| Braintree Laboratories, INC. | $35.92 | 2021 | |
| Cook Medical LLC | $24.97 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $24.91 | 2023 | Dupixent |
| Redhill Biopharma INC. | $24.71 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $19.95 | 2022 | |
| Organon LLC | $14.82 | 2022 | |
| Pfizer INC. | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Biery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.